Research and Markets (http://www.researchandmarkets.com/research/271bae/china_asthma_drug) has announced the addition of the "China Asthma Drug Market Report 2008" report to their offering.
According to the 2004 Global Burden of Asthma Report, there were about 300 million asthma patients worldwide. One out of every 250 disease-related deaths was caused by asthma. In China, the incidence rate of asthma patients has continuously increased in the recent years, especially among urban children. The latest survey shows that the incidence rate is 0.7% - 1.5% in adults and 0.11% - 2.03% in children.
Asthma has been known as a costly disease that is difficult to cure. On average asthma treatment will cost a patient over RMB 3000 per year in China. Assuming a national asthma population of 15 - 18 million and a 10% treatment rate, the cost of asthma treatment will be RMB 4.5 - 5.6 billion.
The Chinese asthma drug market reached RMB 1.7 billion in 1999. In 2007, asthma drug sales were RMB 4.855 billion (USD 714 million), an increase of 22.14% from 2006
This report has systemically analyzed the Chinese asthma drug market. All drug data are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA). Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions.
Market shares from all major players including multinational and Chinese pharmaceutical companies and their major asthma products are analyzed systemically based on data from significant number of Chinese hospitals. The comprehensive hospital utilization data of major asthma drugs will present you a clear picture of the competition landscape of Chinese asthma drug market and the market potential for your company's product(s) that already marketed in China or if you are planning to bring your drugs to the China market.